| 1. |
Chu-Shore CJ, Major P, Camposano S, <italic>et al</italic>. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia, 2010, 51(7): 1236-1241.
|
| 2. |
Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsy chiatric aspects of tuberous sclerosis complex. Lancet Neurol, 2015, 14(5): 733-745.
|
| 3. |
Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neur, 2013, 49(4): 243-254.
|
| 4. |
劉靜, 樸月善, 盧德宏. 結節性硬化相關基因及其表達產物的研究進展. 中華病理學雜志, 2010, 39(3): 210-212.
|
| 5. |
胡湘蜀, 李花, 刁芳明, 等. 癲癇患者 5572 例病因分析. 中華神經科雜志, 2012, 45(4): 244-248.
|
| 6. |
Hilaire C Lam, Julie Nijmeh, Elizabeth P Henske. New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. J Pathol, 2017, 11(241): 219-225.
|
| 7. |
張志芳, 許燮萍, 賈莉娟, 等. 結節性硬化患兒腦電圖及其與臨床的關系. 臨床神經電生理雜志, 2004, 13(1): 25-27.
|
| 8. |
Sharon Samueli, Anastasia Dressler, Gudrun Gr?ppel, <italic>et al</italic>. Everolimus in infants with tuberous sclerosis complex-related West syndrome: First results from a single-center prospective observational study. Epilepsia, 2018, 7(15): 1-5.
|
| 9. |
趙玉武, 孫曉江, 鄭惠民, 等. 結節性硬化癥診斷標準中不同臨床表現發生率的研究. 臨床神經病學雜志, 2006, 19(3): 170.
|
| 10. |
Mettin RR, Merkenschlager A, Bernhard MK, <italic>et al</italic>. Wide spectrum of clinical manifestations in children with tuberous sclerosis complex-follow-up of 20 children. Brain Dev, 2014, 36(4): 306-314.
|
| 11. |
Rosser T, Panigrahy A, McClintock W. The diverse manifestations of the tuberous sclerosis complex: a review. Semin Pediatr Neurol, 2006, 13(1): 27-36.
|
| 12. |
Sun SY. MTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Letters, 2013, 340(1): 1-8.
|
| 13. |
Evan J Hess, Kirsten A Moody, Alexandra L, <italic>et al</italic>. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia, 2017, 7(20): 1-8.
|